# Neovii

Source: https://onco.cc/companies/neovii/  
OnCo record `neovii` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neovii is a Swiss company whose anti-T-lymphocyte globulin, Grafalon, is given before stem cell transplants to lower the risk of graft versus host disease.

## Summary

Neovii, headquartered in Rapperswil-Jona, Switzerland, makes Grafalon (anti-T-lymphocyte globulin, previously ATG-Fresenius), a rabbit-derived polyclonal antibody used in conditioning before allogeneic haematopoietic stem cell transplantation to reduce graft versus host disease and rejection. It has led phase 3 transplant trials in leukaemia registered on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Neovii Biotech; Neovii Biotech GmbH; Neovii Pharmaceuticals AG
- Tags: ctgov-sponsor
- HQ: Rapperswil-Jona
- Type: biotech
- Website: https://www.neovii.com

## Sources

- Official website: https://www.neovii.com
- ClinicalTrials.gov: trials led by Neovii: https://clinicaltrials.gov/search?lead=Neovii

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- terms: [Allogeneic stem cell transplant (allo-SCT)](https://onco.cc/terms/allogeneic-transplant/)

---
JSON: https://onco.cc/api/v1/entities/neovii.json